AUTHOR=Auner S. , Hillebrand C. , Boehm P. M. , Boecker J. , Koren D. , Schwarz S. , Kovacs Z. , Murakoezy G. , Fischer G. , Aigner C. , Hoetzenecker K. , Jaksch P. , Benazzo A. 

TITLE=Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation

JOURNAL=Transplant International

VOLUME=37

YEAR=2024

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12774

DOI=10.3389/ti.2024.12774

ISSN=1432-2277

ABSTRACT=<p>Lung transplantation (LuTx) is an established treatment for patients with end-stage lung diseases, however, outcomes are limited by acute and chronic rejection. One aspect that has received increasing attention is the role of the host’s humoral alloresponse, particularly the formation of <italic>de novo</italic> donor-specific antibodies (dnDSAs). The aim of this study was to investigate the clinical significance of transient and persistent dnDSAs and to understand their impact on outcomes after LuTx. A retrospective analysis was conducted using DSA screening data from LuTx recipients obtained at the Medical University of Vienna between February 2016 and March 2021. Of the 405 LuTx recipients analyzed, 205 patients developed dnDSA during the follow-up period. Among these, 167 (81%) had transient dnDSA and 38 (19%) persistent dnDSA. Persistent but not transient dnDSAs were associated with chronic lung allograft dysfunction (CLAD) and antibody-mediated rejection (AMR) (<italic>p</italic> &lt; 0.001 and <italic>p</italic> = 0.006, respectively). CLAD-free survival rates for persistent dnDSAs at 1-, 3-, and 5-year post-transplantation were significantly lower than for transient dnDSAs (89%, 59%, 56% vs. 91%, 79%, 77%; <italic>p</italic> = 0.004). Temporal dynamics of dnDSAs after LuTx have a substantial effect on patient outcomes. This study underlines that the persistence of dnDSAs poses a significant risk to graft and patient survival.</p>